Skip to content

Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00945581
Enrollment
36
Registered
2009-07-24
Start date
2009-11-30
Completion date
2011-03-31
Last updated
2011-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aged

Keywords

Healthy Elderly volunteers

Brief summary

The primary objectives are to evaluate the effect of AN777 on muscle strength loss that occurs during bed rest, and to investigate whether AN777, in association with resistance training, will support muscle strength recovery following bed rest in healthy elderly subjects.

Interventions

OTHERExperimental Nutritional Powder Formula

Powder twice a day

OTHERPlacebo comparator

Powder twice a day

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to 79 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject (male or female) is \> 60 to \< 79 years of age. * Subject has Body Mass Index (BMI)\> 20 \< 35. * Subject is ambulatory with an SPPB score of \> 9. * Subject agrees to comply with prescribed activity level.

Exclusion criteria

* Subject has undergone major surgery, less than 4 weeks prior to enrollment in the study. * Subject has stated active malignant disease, except basal or squamous cell skin carcinoma or carcinoma in situ of the uterine cervix. * Subject has stated history of diabetes or fasting glucose value \> 126 mg/dL. * Subject has stated presence of partial or full artificial limb. * Subject has stated kidney disease or serum creatinine \> 1.4 mg/dL. * Subject has evidence of cardiovascular disease assessed during resting or exercise EKG. * Subject has untreated hypothyroidism with TSH levels greater than 5.5 microUnits/ml. * Subject has serum glutamate pyruvate transaminase (SGPT) levels greater than two times upper limit of laboratory-designated normal value. * Subject has a history of allergy to any of the ingredients in the study products. * Subject has an obstruction of the gastrointestinal tract precluding ingestion of the study product, inflammatory bowel disease, short bowel syndrome or other major gastrointestinal disease such as gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis. * Subject has stated uncontrolled severe diarrhea, nausea or vomiting. Subject is actively pursuing weight loss. * Subject is currently taking medications/dietary supplements/substances that could modulate metabolism or weight in the opinion of the principal investigator or physician, e.g. progestational agents, steroids, growth hormone, dronabinol, marijuana, beta-hydroxyl-beta-methylbutyrate (HMB), free amino acid supplements, dietary supplements to aid weight loss. Exceptions for multi-vitamin/mineral supplement, inhaled steroids for asthma, topical or optical steroids and short-term use (less than two weeks) of Dexamethasone. * Subject cannot refrain from smoking/discontinue the use of nicotine or tobacco. * Subject has a stated history of Deep Vein Thrombosis (DVT) or a known hypercoaguable condition. * Subject cannot discontinue current anticoagulant therapy. * Subject has refractory anemia with hemoglobin value \< 11.5 g/dL.

Design outcomes

Primary

MeasureTime frame
Lower extremity muscle strength changes after 10 days of bed rest, followed by changes after an 8-week recovery period.10 weeks

Secondary

MeasureTime frame
Lower extremity lean body mass10 weeks
Muscle functionality10 weeks
Total lean mass10 weeks
physical activity levels10 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026